NCT04320771 is a Phase 1 clinical trial of Neladenoson bialanate (BAY 1067197) in Pharmacology, Clinical, sponsored by Bayer.

Who is sponsoring NCT04320771?

NCT04320771 is sponsored by Bayer.

What drugs are being tested in NCT04320771?

Interventions in NCT04320771: Neladenoson bialanate (BAY 1067197).

What condition does NCT04320771 study?

NCT04320771 studies Pharmacology, Clinical.

Is NCT04320771 still recruiting?

NCT04320771 is currently terminated. Last updated 26 March 2020.

Last reviewed 2020-03-26 · How we verify

NCT04320771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Terminated Phase 1 Last updated 26 March 2020

What this trial tests

Phase 1 trial testing Neladenoson bialanate (BAY 1067197) in Pharmacology, Clinical in 18 participants. Terminated before completion.

Timeline

2 November 2017

Primary endpoint
8 August 2018

17 December 2018

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	18
Start date	2 November 2017
Primary completion	8 August 2018
Estimated completion	17 December 2018
Sites	2 locations across Germany

Drugs / interventions tested

Neladenoson bialanate (BAY 1067197) — full drug profile →

Conditions studied

Pharmacology, Clinical — all drugs for Pharmacology, Clinical →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 79, any sex, with Pharmacology, Clinical. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure). Renal impairment which co-occurs in patients with heart failure is a common condition in which the kidneys are not filtering the blood as well as they should. The goal of the study is to learn more about the safety of neladenoson bialanate, how it is tolerated and the way the body absorbs, distributes and excretes the study dug given as a single oral dose of 10 mg immediate release tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adenosine receptors as promising targets for the management of ocular diseases.
Spinozzi E, Baldassarri C, Acquaticci L, Del Bello F, et al · · 2021 · cited 13× · PMID 33519168 · DOI 10.1007/s00044-021-02704-x

Verify or expand the search:

Other trials of Neladenoson bialanate (BAY 1067197)

Trials testing the same drug.

NCT04322253 — Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid · Phase 1 · terminated

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04320771 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 26 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing